A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension
Key facts
- Where
- Incheon, South KoreaSee the site
Where in South Korea
- Gachon University Gil Medical CenterIncheon, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Boryung Pharmaceutical Co., Ltd
- Trial code
- NCT05970237
- Record updated
- 15 September 2025
- Original description
The purpose of this clinical trial is to evaluate the efficacy and safety of dapagliflozin in patient with type 2 diabetes mellitus and hypertensionRead full original descriptionShow less
A Multicenter, Prospective, Non-interventional, Observational Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension
The purpose of this clinical trial is to evaluate the efficacy and safety of dapagliflozin in patient with type 2 diabetes mellitus and hypertension
Inclusion: Those diagnosed with type 2 diabetes mellitus accompanied by hypertension who are scheduled to be administrated Trudapa Tab. or Trudapa M SR Tab; Those who voluntarily signed a written personal information agreement to participate in this clinical study; Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion.
Exclusion: Patients with secondary hypertension: Secondary hypertension is not limited to the following diseases; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.); Those who have a history of taking dapagliflozin within 4 weeks of baseline (Visit 1); Those who are expected to need insulin prescription during the study period; Pregnant women, breast-feeding women.